Dataset Information

Background Proteins in Human Chorionic Gonadotrophin Pharmaceutical Formulations of Different Origin

ABSTRACT: Gonadotrophins, including Human chorionic gonadotrophin (hCG), have been used since and for several decades to treat infertility by ovarian stimulation. The hCG is being extracted from urine of pregnant women and it does inevitably contains other proteins secreted into urine. The presence of other proteins varies from batch to batch and it can be significantly high. Current study investigated the presence of proteins other than hCG in different batches of commercial formulations produced by extraction from urine and by using the recombinant approach. The total protein content varied from batch to batch and a large number of contaminant urinary proteins were identified in all analyzed samples except for the recombinant product

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Urine

DISEASE(S): Infertility,Disease Free

SUBMITTER: Goran Mitulović

LAB HEAD: Goran Mitulović

PROVIDER: PXD010471 | Pride | 2019-03-21

REPOSITORIES: Pride

ACCESS DATA

Publications

Human chorionic gonadotrophin pharmaceutical formulations of urinary origin display high levels of contaminant proteins-A label-free quantitation proteomics study.

Panić-Janković Tanja T Mitulović Goran G

Electrophoresis 20190325 11

To determine whether there is a measurable protein background in different formulations of urinary and recombinant human chorionic gonadotropin (hCG). Primary outcome measures: identification of contaminant proteins in urinary-derived formulations of hCG; secondary outcome measures: quantitative values of contaminant proteins in different batches of urinary -derived hCG formulations. It was found that urinary-derived batches have high presence of contaminant proteins beside the active substance. ...[more]

PMID: 30883802

Similar Datasets

Project description:We previously reported that c-KIT+ human amniotic-fluid derived stem cells obtained from leftover samples of routine II trimester prenatal diagnosis (fetal hAFS) are endowed with regenerative paracrine potential driving pro-survival, pro-angiogenic, anti-fibrotic and proliferative effects on target cells. hAFS can be also isolated from III trimester clinical waste samples during C-section scheduled procedures (perinatal hAFS), thus offering an easily accessible alternative source. Nonetheless, little is known about their paracrine profile. Here we provide a detailed characterization of the hAFS total secretome (i.e. whole of the soluble paracrine factors released by the cells in their conditioned medium, hAFS-CM) and the extracellular vesicles (hAFS-EVs) within it as from II trimester fetal- versus III trimester perinatal cells. Fetal- and perinatal hAFS were characterized and subject to hypoxic preconditioning to enhance their paracrine potential. Their secretome formulations were analyzed in terms of protein and chemokine/cytokine content, with the EV cargo further investigated by RNA sequencing. While the appearance of fetal and perinatal hAFS, along with their corresponding secretome formulations was overlapping, the profiling of their paracrine cargo revealed some differences according to gestational stage and hypoxic preconditioning. While both cell sources provided paracrine formulations enriched with neurotrophic, immunomodulatory and endothelial stimulating factors, the more immature fetal hAFS secretome was defined by a more pronounced pro-angiogenic, pro-resolving and anti-aging profile over the perinatal one, while the corresponfing EV…. Moreover, small RNA profiling showed a relevant enrichment of microRNA in both the fetal and perinatal hAFS-EV cargo, with a steadily expressed pro-resolving miRNA core as reference molecular signature. Here we confirm that hAFS represents an appealing source of regenerative paracrine factors; the selection of either fetal or perinatal hAFS secretome formulations for future paracrine therapy should be evaluated considering the specific clinical scenario.

Dataset Information

Background Proteins in Human Chorionic Gonadotrophin Pharmaceutical Formulations of Different Origin

Publications

Human chorionic gonadotrophin pharmaceutical formulations of urinary origin display high levels of contaminant proteins-A label-free quantitation proteomics study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure